Search Results - "Multani, P.S."

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors by Drilon, A, Marwan, F, Fu, S, Patel, M.R, Olszanski, A.J, Lockhart, A.C, Liu, S.V, Bazhenova, L, Seery, T, Nikolinakos, P, Patel, R, Oliver, J.W, Multani, P.S, Wang, D

“…Background: RXDX-105 is a multikinase inhibitor that has demonstrated potent inhibition of RET and BRAF with biochemical IC50 values of 0.3-0.8 nM against RET…”
Get full text

29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements by Siena, S, Drilon, A.E, Sai-Hong Ou, I, Farago, A.F, Patel, M, Bauer, T.M, Hong, D, Liu, S.V, Lee, J, Patel, R, Schechet, L, Luo, D, Chow Maneval, E, Multani, P.S, De Braud, F.G

Get full text

62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations by Junttila, M., Repellin, C.E., Warne, R., Long, J.E., Sambucetti, L., Ashley, P., Andreatta, G., Baik, J., Salaniwal, S., Colas, C., Romero, A., Soroceanu, L., Patel, R., Maneval, E. Chow, Multani, P.S., Daemen, A., Friedman, L.

Get full text

1345P Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR by Junttila, M.R., Warne, R., Repellin, C., Sambucetti, L., Chang, J., Kim, S., Kim, H.Y., Shin, D.G., Park, D.H., Patel, R., Chow Maneval, E., Multani, P.S., Daemen, A., Friedman, L.

Get full text

1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations by Hong, M.H., Spira, A.I., Lee, K.H., Cho, E.K., Han, J-Y., Shim, B.Y., Lee, J-S., Kao, S.C-H., Kim, S-W., Khattak, A., Patel, M., Xu, R., Wang, J., Ariazi, E., Daemen, A., Chow Maneval, E., Multani, P.S., Patel, R., Ahn, M-J.

Get full text

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 by Demetri, G.D., Paz-Ares, L., Farago, A.F., Liu, S.V., Chawla, S.P., Tosi, D., Kim, E.S., Blakely, C., Krauss, J.C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P.S., Johnson, A.D., Simmons, B., Doebele, R.C.

Get full text

437 - A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors by Drilon, A., Marwan, F., Fu, S., Patel, M.R., Olszanski, A.J., Lockhart, A.C., Liu, S.V., Bazhenova, L., Seery, T., Nikolinakos, P., Patel, R., Oliver, J.W., Multani, P.S., Wang, D.

Get full text

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001 by Demetri, G.D., Paz-Ares, L., Farago, A.F., Liu, S.V., Chawla, S.P., Tosi, D., Kim, E.S., Blakely, C.M., Krauss, J.C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P.S., Johnson, A., Simmons, B., Doebele, R.C.

Get full text

Ex Vivo Treatment of Hematopoietic Stem Cells With 16,16-Dimethyl Prostaglandin E2 (FT1050) Improves Engraftment and Hematopoietic Reconstitution by Cutler, C.S, Desponts, C, Robbins, D, North, T.E, Goessling, W, Kao, G, Ritz, J, Ballen, K.K, Antin, J.H, Spitzer, T.R, SoifferChenY.-B.A., R.J, Ho, V.T, Armand, P, Koreth, J, Alyea, E, McAfee, S, Dey, B.R, Shoemaker, D, Multani, P.S

Get full text

Zevalin radioimmunotherapy offers safe and effective therapy for relapsed or refractory, B cell non-Hodgkin's lymphoma (nhl) by Saleh, M., White, C.A., Witzig, T.E., Gordon, L., Wiseman, G.A., Emmanouilides, C., Murray, J.L., Lister, J., Landin, R., Multani, P.S.

Get full text